Artivion, Inc. (AORT) has a MoatMap StockRank of 25/100 based on Quality (57/100), Value (30/100), and Momentum (25/100) factor scores. The current signal is SELL. Artivion is a specialized medical device company focused on cardiac and vascular surgery. While it has decent quality metrics (Q: 57), it does not fit into our high-conviction CDMO pricing power theme, as it is a product manufacturer rather than a contract services provider.
Artivion, Inc. is a medical device company specializing in the development and manufacturing of innovative products for the surgical treatment of aortic diseases. The company offers a comprehensive portfolio including aortic grafts, stent grafts, and heart valve repair devices, serving a critical niche in cardiovascular surgery. Its competitive strength stems from its specialized expertise, strong clinical evidence, and established relationships within the global cardiac surgery community.
| Price | $20.88 |
| Market Cap | $1.1B |
| P/E (TTM) | 83.36 |
| P/E (Forward) | 26.95 |
| Price/Book | 2.24 |
| Return on Equity | 3.1% |
| Return on Invested Capital | 5.3% |
| Debt/Equity | 57.31 |
| Gross Margin | 64.6% |
| Operating Margin | 5.2% |
| Revenue Growth | 17.5% |
| Free Cash Flow | $-7M |
Artivion, Inc. operates in the Medical Devices industry, part of the Healthcare sector (United States).